VISLYFA

Serial Number 98479479
730

Registration Progress

Application Filed
Apr 2, 2024
Under Examination
Feb 4, 2025
Approved for Publication
Dec 10, 2024
Published for Opposition
Dec 10, 2024
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Aug 04, 2025 1 days

Trademark Image

VISLYFA

Basic Information

Serial Number
98479479
Filing Date
April 2, 2024
Published for Opposition
December 10, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Jul 16, 2025
Application
Pending
Classes
005

Rights Holder

LUPIN INC.

03
Address
111 South Calvert Street
Harbor place Tower, 21st Floor
Baltimore, MD 21202

Ownership History

LUPIN INC.

Original Applicant
03
Baltimore, MD

LUPIN INC.

Owner at Publication
03
Baltimore, MD

Legal Representation

Attorney
Danielle I Mattessich

USPTO Deadlines

Next Deadline
1 days remaining
NOA E-Mailed - SOU Required
Due Date
August 04, 2025
Extension Available
Until February 04, 2026

Application History

12 events
Date Code Type Description Documents
Jul 17, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 16, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 16, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 16, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 4, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 10, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 10, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 4, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 17, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 15, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 2, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 2, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Biological preparations for the treatment of eye conditions, namely, to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO); Biological preparations for the treatment of eye diseases; Biological preparations for use in intravitreal medicinal therapy; Pharmaceutical preparations for the treatment of wet AMD, DME and RVO; Pharmaceutical preparations for the treatment of eye diseases; Pharmaceutical preparations for slowing the growth of blood vessels in the eye, namely, anti-VEGF intravitreal injections; Pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye

Classification

International Classes
005